Dainippon Sumitomo: Pipeline, Products, Performance, Potential

Date: January 22, 2010
Pages: 84
Price:
US$ 1,040.00
Publisher: Espicom Business Intelligence
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: D6BCE5C2743EN
Leaflet:

Download PDF Leaflet

Dainippon Sumitomo: Pipeline, Products, Performance, Potential
Dainippon Sumitomo Pharma (DSP) is a research-based pharmaceutical company, headquartered in Osaka, which has resulted from the merger of Dainippon Pharmaceutical (which acts as the surviving company) and Sumitomo Pharmaceutical (a division of Sumitomo Chemical).

The merger was finalised and operations began on 1st October 2005, with the new company becoming the fifth largest pharmaceutical company in Japan. DSP is listed as a consolidated subsidiary of Sumitomo Chemical, which owns 50.1 per cent of the outstanding shares.

Since the merger, DSP is active in a range of therapeutic areas, principally Cardiovascular; Oncology/ Infection; Gastrointestinal; Central Nervous System (CNS); Inflammation/Allergy; and Diabetes. In the future, DSP intends to focus its product base on CNS diseases and the treatment of diabetes and associated complications.
EXECUTIVE SUMMARY

A detailed and comprehensive overview of current financial position, company strategy, product and pipeline analysis.

THERAPEUTIC AREA FOCUS

Key product analysis and forecasting
Cardiovascular
  Amlodin (amlodipine)
  Avapro (irbesartan)
  Ephedrine Nagai (ephedrine hydrochloride)
  ProRenal (limaprost alfadex)
Oncology/Infection
  AmBisome (amphotericin B)
  Meropen/Merrem (meropenem)
Gastrointestinal
  Gasmotin (mosapride citrate)
Inflammation/Allergy
  Ebastel (ebastine)
  QVAR (beclomethasone dipropionate)
Central Nervous System
  Excegran/Exogran/Zonegran/Tremode/Trerief (zonisamide)
  Lonasen (blonanserin)
Diabetes
  Seibule (miglitol)

OPERATIONAL DATA

A wealth of background and detail
A full 5-year financial performance assessment
Key corporate events
Key agreements
Infrastructure
Subsidiaries and joint ventures
Skip to top


Eisai: Pipeline, Products, Performance, Potential US$ 1,040.00 Nov, 2009 · 118 pages
Takeda Pipeline, Products, Performance, Potential US$ 1,040.00 Nov, 2009 · 124 pages
Biogen Idec: Pipeline, Products, Performance, Potential US$ 1,040.00 Jan, 2010 · 86 pages
Chugai: Pipeline, Products, Performance, Potential US$ 1,040.00 Oct, 2009 · 80 pages

Ask Your Question

Dainippon Sumitomo: Pipeline, Products, Performance, Potential
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: